TransMedics Group, Inc. (NASDAQ:TMDX) Shares Purchased by Principal Financial Group Inc.

Principal Financial Group Inc. increased its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 260.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 202,287 shares of the company’s stock after buying an additional 146,115 shares during the period. Principal Financial Group Inc. owned about 0.61% of TransMedics Group worth $31,759,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. International Assets Investment Management LLC acquired a new stake in shares of TransMedics Group during the 2nd quarter valued at approximately $47,000. USA Financial Formulas bought a new position in TransMedics Group during the 3rd quarter valued at $55,000. J.Safra Asset Management Corp increased its position in shares of TransMedics Group by 649.2% during the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after purchasing an additional 383 shares during the period. Signaturefd LLC raised its position in TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after acquiring an additional 93 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its stake in TransMedics Group by 187.0% during the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after purchasing an additional 316 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $9,457,269.06. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the transaction, the director now owns 732 shares of the company’s stock, valued at $61,158.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the sale, the chief executive officer now owns 61,643 shares in the company, valued at approximately $9,457,269.06. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 36,958 shares of company stock valued at $5,230,528 over the last three months. 7.00% of the stock is owned by insiders.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Oppenheimer reduced their price target on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a research report on Tuesday, October 29th. Needham & Company LLC decreased their price target on shares of TransMedics Group from $208.00 to $109.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th. JPMorgan Chase & Co. lowered their price objective on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 29th. Piper Sandler restated an “overweight” rating and set a $180.00 target price on shares of TransMedics Group in a research report on Tuesday, October 29th. Finally, Morgan Stanley raised their price objective on shares of TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $144.80.

TransMedics Group Trading Up 3.6 %

NASDAQ TMDX opened at $89.11 on Tuesday. The stock’s 50 day moving average price is $132.03 and its two-hundred day moving average price is $139.89. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The stock has a market capitalization of $2.99 billion, a price-to-earnings ratio of 91.47 and a beta of 2.08. TransMedics Group, Inc. has a 52 week low of $56.83 and a 52 week high of $177.37.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). The business had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company’s quarterly revenue was up 63.7% compared to the same quarter last year. During the same period last year, the firm earned ($0.12) earnings per share. As a group, analysts anticipate that TransMedics Group, Inc. will post 1.07 earnings per share for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.